5 recruiting, 1 not yet recruiting, 1 withdrawn. 3 Phase 3, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Not applicable | 2 | Recruiting 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Swiss GO Trial Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management Metamizole, Ibuprofen, Placebo - Cancer Pain, Cancer Palliative Care | Phase 3 | Not yet recruiting | University Hospital, Basel, Switzerland | 318 | 2026-10-01 | 2026-08-19 |
| Stress Reduction Through Acupuncture Acupuncture, Standard supportive care - Acupuncture, Breast Cancer | Not applicable | Recruiting | Isabell Xiang Ge | 112 | 2026-07-07 | 2026-07-09 |
| OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling, Carboplatin / Paclitaxel Chemotherapy - Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | Not applicable | Recruiting | Swiss GO Trial Group | 135 | 2025-03-31 | 2026-10-16 |
| Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms Adenomyosis of Uterus | Recruiting | Swiss GO Trial Group | 1000 | 2024-03-15 | 2026-10-16 | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer Standard treatment: Control arm, Experimental arm - Cervical Carcinoma, Adenocarcinoma | Phase 3 | Recruiting | Institut Claudius Regaud | 510 | 2023-12-20 | 2026-10-13 |
| APX005M in Patients With Recurrent Ovarian Cancer APX005M - Ovarian Cancer | Phase 2 | Withdrawn | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2023-09-07 | 2023-09-11 | |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Letrozole 2.5mg, Placebo - Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Swiss GO Trial Group | 540 | 2020-11-05 | 2025-09-29 |
Fallopian Tube Neoplasms (2) · Abdominal Pain (1) · Adenocarcinoma (1) · Adenomyoma (1) · Adenomyosis (1) · Breast Neoplasms (1) · Cancer Pain (1) · Carcinoma, Adenosquamous (1) · Dysmenorrhea (1) · Dyspareunia (1) · Hemostatic Disorders (1) · Infertility (1) · Menorrhagia (1) · Metrorrhagia (1) · Myoma (1)
Carboplatin (2) · 1-dodecylpyridoxal (1) · Acupuncture Therapy (1) · Dipyrone (1) · Ibuprofen (1) · Letrozole (1) · Radiotherapy (1) · sotigalimab (1)
Switzerland (5) · Spain (2) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Poland (1)
Christopher Boehlke, Prof. Dr. (1) · Gwendolin Manegold-Brauer, Prof. Dr. (1) · Mansoor R Mirza (1) · Viola Heinzelmann-Schwarz, Prof. (1) · Viola Heinzelmann-Schwarz, Prof.MD (1)
2019 (1), 2023 (1), 2025 (1)